Multifocal myoclonus as a presentation of levetiracetam toxicity

被引:3
作者
Nasif, Mei Bou [1 ]
Varade, Shweta [1 ]
Koubeissi, Mohamad Z. [1 ]
机构
[1] George Washington Univ, Dept Neurol, 2150 Penn Ave NW, Washington, DC 20037 USA
来源
CLINICAL NEUROPHYSIOLOGY PRACTICE | 2021年 / 6卷
关键词
Levetiracetam; Multifocal myoclonus; Pharmacology; SAFETY; OVERDOSE; EFFICACY; SEIZURES; CHILDREN;
D O I
10.1016/j.cnp.2021.10.004
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Levetiracetam (LEV) is widely used for treatment of focal and myoclonic seizures, but reports of LEV toxicity are scarce. Here, we report a rare case of multifocal myoclonus due to LEV toxicity in a patient with chronic renal insufficiency. Case presentation: A 52-year-old woman with history of chronic kidney disease was admitted to the ICU for sedation and intubation after a cardiac arrest. She developed nonconvulsive status epilepticus that resolved after administration of propofol while receiving LEV 1500 mg twice a day. After holding the propofol infusion, the patient started having multifocal myoclonic jerks, documented on video-EEG recordings with a supratherapeutic level of LEV. After discontinuation of LEV, the myoclonus resolved. Conclusion: This is a unique manifestation of LEV toxicity, which has been scarce in the literature. It suggests an inverted U-shaped dose-response of the antimyoclonic effect of LEV. (C) 2021 International Federation of Clinical Neurophysiology. Published by Elsevier B.V.
引用
收藏
页码:281 / 284
页数:4
相关论文
共 20 条
  • [1] Abou-Khalil Bassel, 2008, Neuropsychiatr Dis Treat, V4, P507
  • [2] Accidental overdosage of levetiracetam in two children caused no side effects
    Awaad, Yasser
    [J]. EPILEPSY & BEHAVIOR, 2007, 11 (02) : 247 - 247
  • [3] A case of levetiracetam (Keppra®) poisoning with clinical and toxicokinetic data
    Barrueto, F
    Williams, K
    Howland, MA
    Hoffman, RS
    Nelson, LS
    [J]. JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 2002, 40 (07): : 881 - 884
  • [4] Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study
    Beran, RG
    Berkovic, SF
    Black, AB
    Danta, G
    Hiersemenzel, R
    Schapel, GJ
    Vajda, FJE
    [J]. EPILEPSY RESEARCH, 2005, 63 (01) : 1 - 9
  • [5] Chayasirisobhon Sirichai, 2010, Acta Neurol Taiwan, V19, P292
  • [6] Levetiracetam-induced pediatric toxic epidermal necrolysis successfully treated with etanercept
    Estebanez, Andrea
    Saez-Martin, Luis Carlos
    Munoz, Juan Ignacio
    Silva, Esmeralda
    Monrabal, Alicia
    Monteagudo, Carlos
    Ramon, Maria Dolores
    [J]. PEDIATRIC DERMATOLOGY, 2020, 37 (04) : 701 - 705
  • [7] Pancytopenia Associated with Levetiracetam Treatment
    Gallerani, Massimo
    Mari, Elisa
    Boari, Benedetta
    Carletti, Rossella
    Marra, Anna
    Cavallo, Michele
    [J]. CLINICAL DRUG INVESTIGATION, 2009, 29 (11) : 747 - 751
  • [8] Efficacy and safety of levetiracetam in children with partial seizures: An open-label trial
    Glauser, TA
    Pellock, JM
    Bebin, EM
    Fountain, NB
    Ritter, FJ
    Jensen, CM
    Shields, WD
    [J]. EPILEPSIA, 2002, 43 (05) : 518 - 524
  • [9] Adverse Skin Reactions with Antiepileptic Drugs Using Korea Adverse Event Reporting System Database, 2008-2017
    Kim, Hyun Kyung
    Kim, Dae Yeon
    Bae, Eun-Kee
    Kim, Dong Wook
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2020, 35 (04)
  • [10] Overdose with levetiracetam: a case report and review of the literature
    Larkin, T. M.
    Cohen-Oram, A. N.
    Catalano, G.
    Catalano, M. C.
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2013, 38 (01) : 68 - 70